Cargando…

Entrectinib-Induced Heart Failure in a Patient With Metastatic Lung Adenocarcinoma: A Case Report

Entrectinib is a recently approved multikinase inhibitor to treat advanced c-ros oncogene1 (ROS1) positive non-small cell lung cancer (NSCLC). Although molecular targeted therapy is generally well tolerated, cardiovascular adverse events have been described in recent years. We report a case of NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Otsu, Yukiko, Kata, Yuki, Takayasu, Hirokazu, Inoue, Satoshi, Kaneko, Takeshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cureus 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808486/ https://www.ncbi.nlm.nih.gov/pubmed/36605067 http://dx.doi.org/10.7759/cureus.32174

Ejemplares similares

ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report
por: Takayasu, Hirokazu, et al.
Publicado: (2023)

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib
por: Lazzari, Chiara, et al.
Publicado: (2022)

Crizotinib Efficacy After Progression With Entrectinib in ROS1-Positive Lung Cancer: A Case Report
por: Taban, Hakan, et al.
Publicado: (2022)

Rare MYH9-ROS1 Fusion Gene-Positive Lung Adenocarcinoma Showing Response to Entrectinib Treatment: A Case Study
por: Tsuda, Takeshi, et al.
Publicado: (2022)

Case Report: A case of complete response to entrectinib in NTRK fusion gene-positive parotid gland cancer
por: Moriyama, Etsuko, et al.
Publicado: (2023)

Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib
por: Wu, Wen-Chi, et al.
Publicado: (2023)

Entrectinib-induced Brugada phenocopy in a patient with metastatic non-small cell lung cancer
por: Kubota, Megumi, et al.
Publicado: (2023)

TRK Inhibition with Entrectinib in Metastatic Salivary Secretory Carcinoma (SC): A Case Report
por: Ernst, Matthew S., et al.
Publicado: (2022)

Development of Neuropathic Arthropathy With Entrectinib: Case Report
por: Giustini, Nicholas P., et al.
Publicado: (2022)

Entrectinib for non-small cell lung cancer and solid tumours
Publicado: (2020)

A Case of Metastatic Urachal Carcinoma Treated With FOLFIRI (irinotecan and 5-Fluorouracil/leucovorin) Plus Bevacizumab
por: Kanamaru, Tomohiro, et al.
Publicado: (2014)

A case of metastatic lung adenocarcinoma of the bladder in a patient with no documented history of lung cancer
por: Azaiza, Mohammed, et al.
Publicado: (2023)

The Potential Long-Term Comparative Effectiveness of Larotrectinib and Entrectinib for Second-Line Treatment of TRK Fusion-Positive Metastatic Lung Cancer
por: Roth, Joshua A., et al.
Publicado: (2020)

Entrectinib in the neoadjuvant setting of anaplastic thyroid cancer: a case report
por: Damásio, Inês, et al.
Publicado: (2022)

Sensitivity to Entrectinib Associated With a Novel LMNA-NTRK1 Gene Fusion in Metastatic Colorectal Cancer
por: Sartore-Bianchi, Andrea, et al.
Publicado: (2015)

Entrectinib for NTRK Fusion-Positive Metastatic Melanoma Progressing on Combined PD-1 and CTLA-4 Inhibition: A Case Report
por: Dawood, Shaheenah, et al.
Publicado: (2023)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
por: Pacenta, Holly L, et al.
Publicado: (2018)

Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2019)

Case report: Rosai-Dorfman disease with rare extranodal lesions in the pelvis, heart, liver and skin
por: Yoshida, Misaki, et al.
Publicado: (2023)

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)
por: Desai, Ami V, et al.
Publicado: (2022)

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer
por: Dziadziuszko, Rafal, et al.
Publicado: (2021)

A RESPONSE TO “THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER”
por: Ogale, Sarika, et al.
Publicado: (2020)

Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma
por: Yang, Szu-Chun, et al.
Publicado: (2022)

Re-challenge of Platinum-based Chemotherapy for Platinum-refractory Patients with Recurrent or Metastatic Head and Neck Cancer: Claims Data Analysis in Japan
por: Tahara, Makoto, et al.
Publicado: (2020)

A rare case of metastatic sigmoid adenocarcinoma to the ureter
por: Peifer, David, et al.
Publicado: (2019)

Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer
por: Farago, Anna F., et al.
Publicado: (2015)

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
por: Sehgal, Kartik, et al.
Publicado: (2020)

Entrectinib—A SARS-CoV-2 Inhibitor in Human Lung Tissue (HLT) Cells
por: Peralta-Garcia, Alejandro, et al.
Publicado: (2021)

A case of lung adenocarcinoma with a novel CD74‐ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib
por: Hashiguchi, Mizuha Haraguchi, et al.
Publicado: (2021)

Entrectinib dose confirmation in pediatric oncology patients: pharmacokinetic considerations
por: Meneses-Lorente, Georgina, et al.
Publicado: (2023)

Papillary Adenocarcinoma: A Rare Subtype of Lung Adenocarcinoma
por: Thouil, Afaf, et al.
Publicado: (2023)

Case Report: An Unusual Case of Pulmonary Metastatic Adenocarcinoma From Low-Grade Appendiceal Mucinous Neoplasms
por: Zhao, Xin-Yu, et al.
Publicado: (2022)

Lung malignancy in prostate cancer: A report of both metastatic and primary lung lesions
por: Reinstatler, Lael, et al.
Publicado: (2017)

Heart Failure With Reduced Ejection Fraction Caused by Osimertinib in a Patient With Lung Cancer: A Case Report and Literature Review
por: Okuzumi, Shinichi, et al.
Publicado: (2022)

Case Report: Short-Term Response to First-Line Crizotinib Monotherapy in a Metastatic Lung Adenocarcinoma Patient Harboring a Novel TPR-ROS1 Fusion
por: Wei, Shuli, et al.
Publicado: (2022)

Case Report: Lung Adenocarcinoma Initially Presenting With Cutaneous and Subcutaneous Metastases
por: Wang, Jingjing, et al.
Publicado: (2022)

Lung adenocarcinoma with bladder metastasis: A case report and literature review
por: Liu, Yuying, et al.
Publicado: (2023)

Case Report: Systemic Treatment and Serial Genomic Sequencing of Metastatic Prostate Adenocarcinoma Progressing to Small Cell Carcinoma
por: Lu, XiaoJun, et al.
Publicado: (2021)

Entrectinib for ROS1‐rearranged non‐small cell lung cancer after crizotinib‐induced interstitial lung disease: A case report
por: Tanimura, Mai, et al.
Publicado: (2021)

Renal vein tumor thrombus from metastatic anal gland adenocarcinoma
por: Bernstein, Ari, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_mh608ra6uhhuracrvfrsrb741s